

# 1 Predicting emergent Dolutegravir resistance in South Africa:

## 2 A modelling study

3 Tom Loosli<sup>1,2</sup>, Anthony Hauser<sup>1,2,3,4</sup>, Johannes Josi<sup>1,2</sup>, Nuri Han<sup>1,2</sup>, Suzanne M Ingle<sup>5</sup>, Ard van Sighem<sup>6</sup>,  
4 Linda Wittkop<sup>7,8,9</sup>, Janne Vehreschild<sup>10,11,12</sup>, Francesca Ceccherini-Silberstein<sup>13</sup>, Gary Maartens<sup>14</sup>, M  
5 John Gill<sup>15,16</sup>, Caroline A Sabin<sup>17</sup>, Leigh F Johnson<sup>18</sup>, Richard Lessells<sup>19,20</sup>, Huldrych F Günthard<sup>1,2</sup>,  
6 Matthias Egger<sup>3,5,18</sup>, Roger D Kouyos<sup>1,2</sup>  
7

- 8 1. Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland (Tom Loosli  
9 Msc, Anthony Hauser PhD, Johannes Josi PhD, Nuri Han Msc, Prof Huldrych F Günthard MD, Prof Roger D Kouyos PhD)  
10 2. Institute of Medical Virology, University of Zurich, Zurich, Switzerland (Tom Loosli, Anthony Hauser, Johannes Josi, Nuri  
11 Han, Prof Huldrych F Günthard, Prof Roger D Kouyos)  
12 3. Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland (Anthony Hauser, Prof Matthias  
13 Egger MD)  
14 4. INSERM, Sorbonne Université, Pierre Louis Institute of Epidemiology and Public Health, Paris, France (Anthony Hauser)  
15 5. Population Health Sciences, Bristol Medical School, University of Bristol, UK (Suzanne M. Ingle PhD, Prof Matthias Egger)  
16 6. Stichting hiv monitoring, Amsterdam, the Netherlands (Ard van Sighem PhD)  
17 7. Univ. Bordeaux, INSERM, Institut Bergonié BPH U1219, CIC-EC 1401, Bordeaux, F-33000, France (Prof Linda Wittkop PhD)  
18 8. INRIA SISTM Team, Talence, France (Prof Linda Wittkop)  
19 9. CHU de Bordeaux, Service d'information Médicale, INSERM, Institut Bergonié, CIC-EC 1401, Bordeaux, F-33000, France  
20 (Prof Linda Wittkop)  
21 10. Department II of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt, Frankfurt Am Main, Germany  
22 (Prof Janne Vehreschild MD)  
23 11. Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne,  
24 Cologne, Germany (Prof Janne Vehreschild)  
25 12. German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany (Prof Janne Vehreschild)  
26 13. Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy (Prof Francesca Ceccherini-  
27 Silberstein PhD)  
28 14. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa (Prof  
29 Gary Maartens MD)  
30 15. Southern Alberta Clinic, Calgary, AB, Canada (Prof M John Gill MD)  
31 16. Department of Medicine, University of Calgary, Calgary, AB, Canada (Prof M John Gill)  
32 17. Institute for Global Health, University College London, UK (Prof Caroline A Sabin PhD)  
33 18. Centre for Infectious Disease Epidemiology and Research, School of Public Health, University of Cape Town, Cape Town,  
34 South Africa (Prof Leigh F Johnson PhD, Prof Matthias Egger)  
35 19. KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), University of KwaZulu-Natal, Durban, South  
36 Africa (Richard Lessells PhD)  
37 20. Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa (Richard Lessells)

38  
39 Correspondence to:  
40 Tom Loosli (tom.loosli@uzh.ch)  
41 Roger Kouyos (roger.kouyos@uzh.ch)  
42  
43

## 44 **Summary**

45 **Background:** In response to the rising prevalence of non-nucleoside reverse transcriptase inhibitors  
46 (NNRTIs) resistance, millions of people living with HIV (PWH) have switched to dolutegravir-based  
47 antiretroviral therapy (ART). Understanding the possible emergence of dolutegravir resistance is  
48 essential for health policy and planning. We developed a mathematical model to predict the trends  
49 of dolutegravir resistance in PWH in South Africa.

50 **Methods:** MARISA (Modelling Antiretroviral drug Resistance In South Africa) is a deterministic  
51 compartmental model consisting of four layers: (i) the cascade of care, (ii) disease progression, (iii)  
52 gender, and (iv) drug resistance. MARISA was calibrated to reproduce the HIV epidemic in South  
53 Africa. We assumed dolutegravir was introduced in 2020. We extended the model by including key  
54 resistance mutations observed in PWH experiencing virologic failure on dolutegravir-based ART  
55 (G118K, E138AKT, G140ACS, Q148HKNR, N155H, and R263K). Model outcomes were acquired (ADR)  
56 and transmitted drug resistance (TDR) to dolutegravir and NNRTIs stratified by duration on failing  
57 dolutegravir-based ART and under different counterfactual scenarios of switching to protease-  
58 inhibitor (PI)-based ART.

59 **Finding:** The model predicts that ADR will increase rapidly, from 18.5% (uncertainty range 12.5% to  
60 25.4%) in 2023 to 46.2% (32.9% to 58.9%) in 2040. The prevalence of ADR in 2040 increased with the  
61 duration of virologic failure on dolutegravir-based ART: 18.0% (12.2% to 23.7%) for 6 months of  
62 failing ART compared to 54.8% (41.1% to 63.9%) for over 1.5 years. For TDR, the model predicts a  
63 slow but steady increase from 0.1% (0.1% to 0.2%) in 2023 to 8.8% (4.4% to 17.3%) in 2040.  
64 Transmitted NNRTI resistance will cease to increase but remain prevalent at 7.7% in 2040. Rapid  
65 resistance testing-informed switching to PI-based ART would substantially reduce both ADR and  
66 TDR.

67 **Interpretation:** The prevalence of dolutegravir ADR and TDR will likely increase, with the 10%  
68 threshold of TDR possibly reached by 2035, depending on monitoring and switching strategies. The  
69 increase will likely be greater in settings where resources for HIV-1 RNA monitoring and resistance  
70 testing or options for switching to alternative ART regimens are limited.

71 **Funding:** Swiss National Science Foundation, National Institutes of Health, UZH URPP Evolution in  
72 Action

73

## 74 **Research in context**

### 75 **Evidence before this study**

76 Dolutegravir has demonstrated high efficacy, even in individuals with compromised backbone drugs.  
77 We searched Scopus on April 15 2024, using free text words dolutegravir and resistance. We did not  
78 identify any modelling studies attempting to predict dolutegravir resistance trends in the coming  
79 years. A recent collaborative analysis of predominantly European cohort studies involving 599  
80 people living with HIV (PWH) who underwent genotypic resistance testing at the point of  
81 dolutegravir-based treatment failure showed that the risk of dolutegravir resistance increases  
82 significantly in the presence of Nucleoside Reverse Transcriptase Inhibitor (NRTI) resistance. This is  
83 particularly concerning in settings such as South Africa, where a high proportion of individuals  
84 already exhibit NRTI resistance. Indeed, recent surveys in South Africa already hint at rapidly  
85 increasing levels of acquired dolutegravir resistance.

### 86 **Added value of this study**

87 This study is the first to model the likely dynamics of dolutegravir resistance in South Africa.  
88 Covering the period 2020 to 2040, it extends a previous model of antiretroviral drug resistance  
89 evolution in South Africa to dolutegravir-based ART. The results indicate that while dolutegravir  
90 resistance is currently low, it will increase at the population level, and transmitted dolutegravir  
91 resistance may exceed 10% by around 2035, depending on the duration PWH spend on failing  
92 dolutegravir-based ART. Interventions such as switching to protease-inhibitor (PI)-based ART based  
93 on genotypic resistance tests could reduce or even curb the rise of dolutegravir resistance.

### 94 **Implications of all the available evidence**

95 Dolutegravir resistance may undermine the success of integrase strand transfer inhibitor (INSTI)-  
96 based ART in South Africa, where the guidelines limit drug resistance testing to PWH with repeated  
97 viral load measurements above 1,000 copies/mL and evidence of good adherence. Monitoring the  
98 evolution of dolutegravir resistance at the population level is crucial to inform future changes in  
99 guidelines on drug resistance testing and switching to PI-based ART.

100

## 101 Introduction

102 In response to the rising prevalence of drug resistance to non-nucleoside reverse transcriptase  
103 inhibitors (NNRTIs), the World Health Organization (WHO) has recommended the integrase strand  
104 transfer inhibitor (INSTI) dolutegravir as first- and second-line antiretroviral therapy (ART) for all  
105 people living with HIV (PWH) since 2018.<sup>1</sup> By July 2022, dolutegravir had been adopted as the  
106 preferred first-line ART in 108 countries,<sup>2</sup> including South Africa, where over 7.5 million people live  
107 with HIV.<sup>3</sup> Dolutegravir-based ART has a higher genetic barrier to resistance than the previously  
108 recommended non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line regimens.<sup>4</sup>  
109 Dolutegravir-resistant HIV is currently rare in PWH on first-line ART but is observed more frequently  
110 in treatment-experienced people in trials,<sup>5</sup> observational cohorts,<sup>6,7</sup> and national surveys.<sup>8-10</sup> A  
111 collaborative analysis of eight large cohort studies combined data from 599 individuals, primarily  
112 from Europe, who experienced viremia on dolutegravir-based ART and underwent genotypic  
113 resistance testing (GRT). At least one major or accessory INSTI drug resistance mutation (DRM) was  
114 found in 86 (14%) study participants, and 23 (3.8%) had high or intermediate levels of predicted  
115 resistance to dolutegravir.<sup>6</sup>

116 In South Africa, the current treatment guidelines recommend GRT only for people who have two or  
117 more viral load measurements exceeding 1,000 copies/mL and have been on dolutegravir-based or  
118 protease inhibitor (PI)- ART for over two years with good adherence.<sup>11</sup> Consequently, individuals  
119 often remain viremic for prolonged periods.<sup>12-14</sup> Furthermore, switching to alternative regimens,  
120 such as protease inhibitor (PI)-based regimens, is relatively uncommon among those on failing  
121 dolutegravir-based ART.<sup>15</sup> Together, these factors may facilitate the emergence and spread of HIV  
122 drug resistance.

123 MARISA (Modelling Antiretroviral drug Resistance In South Africa) is a mathematical model that  
124 simulates the HIV epidemic and NNRTI resistance dynamics in South Africa.<sup>16,17</sup> We updated the  
125 model to include a dimension for dolutegravir resistance, allowing us to study the emergence of  
126 acquired and transmitted resistance to dolutegravir. We aimed to predict how dolutegravir  
127 resistance levels will change over time to assess if the drug will stay effective in the long run or if  
128 resistance will rise rapidly, similar to what happened with the NNRTIs.

129

## 130 **Methods**

### 131 **The MARISA model**

132 Described in detail elsewhere,<sup>16</sup> MARISA is a deterministic compartmental model of the HIV-1  
133 epidemic in South Africa from 2005 to 2040 using monthly time steps. Briefly, it consists of four  
134 dimensions: i) the continuum of care from HIV infection through to the diagnosis and initiation of  
135 ART, suppressive ART (viral load < 1'000 copies per ml) and failing ART (viral load  $\geq$  1'000 copies per  
136 ml), and possible transfer to PI-based ART; ii) disease progression, with four CD4 count groups (>  
137 500, 350 – 500, 200 – 349, and < 200 cells/ $\mu$ L); iii) gender; iv) drug resistance (appendix p3). MARISA  
138 was calibrated to reproduce the HIV epidemic in South Africa using data from the leDEA  
139 collaboration<sup>18</sup> and the literature and fitted to estimates of the demographic and epidemiological  
140 Thembisa model.<sup>19</sup> We assumed the introduction of dolutegravir started in 2020. Rates of initiation  
141 and switching to dolutegravir-based ART are described elsewhere<sup>17</sup> and in the appendix (p4-5).

142 The original implementation of MARISA treated resistance as two states (susceptible or resistant),  
143 which is appropriate for antiretroviral drugs with a low genetic barrier, such as NRTIs and NNRTIs.  
144 However, this approach is unsuitable for dolutegravir, which has a higher genetic barrier.<sup>4</sup> We  
145 included the drug resistance mutations observed in the DTG RESIST study, i.e., G118K, E138AKT,  
146 G140ACS, Q148HKNR, N155H, and R263K.<sup>6</sup> These six DRMs cover all mutations identified as  
147 signature DRMs for dolutegravir resistance.<sup>20</sup> R263K was assumed to occur in isolation, whereas  
148 G140ACS and Q148HKNR, and G118R and E138K occurred in combination, in line with a recent  
149 review of acquired dolutegravir drug resistance mutations.<sup>20</sup> The resulting genotypes (see Figure 1)  
150 were classified as susceptible, potential-low, low, intermediate, and high-level dolutegravir  
151 resistance according to the Stanford resistance algorithm.<sup>21</sup> As in Hauser et al.,<sup>16,17</sup> we included  
152 resistance for NRTI and NNRTI (susceptible or resistant), resulting in total in 48 drug resistance  
153 compartments. We expanded the treatment cascade, stratifying the treatment failure  
154 compartments according to the average duration on failing ART (< 6 months, 6 months to 1.5 years,  
155 > 1.5 years). Finally, we modified the model to include out-of-care dynamics, whereby individuals on  
156 failing dolutegravir-based ART may leave and re-enter care (Figure 1). See appendix p6-7 for further  
157 details.

158

### 159 **Definitions, parameters and calibration**

160 We defined transmitted dolutegravir resistance as the proportion of people with intermediate or  
161 high levels of dolutegravir resistance at diagnosis. Acquired drug resistance was defined as the

162 proportion of people on a failing dolutegravir-based regimen with intermediate or high-level  
163 dolutegravir resistance.

164 Key model parameters included (i) acquisition and (ii) reversion rates of dolutegravir resistance  
165 mutations, (iii) the impact of NRTI resistance on dolutegravir resistance acquisition, (iv) the impact of  
166 dolutegravir resistance on dolutegravir treatment efficacy, (v) the probability of transmission  
167 dolutegravir DRMs compared to NNRTI resistance transmission, and (vi) the proportion on failing  
168 dolutegravir-based ART with detectable drug levels. Based on the DTG RESIST study,<sup>6</sup> we assume  
169 that NRTI resistance increases the risk of acquiring dolutegravir DRMs upon treatment failure  
170 (appendix page 10). We estimated mutation-specific acquisition rates based on an estimated  
171 duration of 3 months of failing dolutegravir-based ART in the DTG RESIST study. The reversal of  
172 dolutegravir resistance mutations is not well documented but may occur rapidly.<sup>22</sup> We assumed an  
173 average duration to reversion of two years for each mutation with HIV replicating in the absence of  
174 dolutegravir. We assumed that high- and intermediate-level dolutegravir resistance increases the  
175 treatment failure rate on dolutegravir-based ART: for high-level resistance, the impact is equal to  
176 that of high-level NNRTI resistance on NNRTI-based ART; for intermediate resistance, the effect is  
177 halved. The probability of transmitting dolutegravir resistance mutations in an HIV transmission  
178 event is unknown, but cases have been documented.<sup>23</sup> We assumed an equal transmission rate for  
179 dolutegravir resistant strains as for susceptible strains, and explored decreased rates in sensitivity  
180 analyses (allowing for up to 20 times decreased transmission rates in resistant strains). The  
181 parameters included in MARISA and its calibration are described in detail in the appendix (p4-11).

182 To construct plausible ranges of model outcomes (predicted dolutegravir ADR and TDR) that reflect  
183 the uncertainty in the choice of parameter values, we defined an uncertainty range using pessimistic  
184 (favouring the emergence of resistance) or optimistic (impeding the emergence of resistance)  
185 parameter values in addition to our baseline parameterisation (Table 1 and appendix p12).

## 186 **Counterfactual scenarios**

187 In counterfactual scenarios, we investigate the impact of interventions such as those proposed in  
188 the RESOLVE trial<sup>24</sup> on transmitted and acquired dolutegravir resistance. Specifically, we compared  
189 our baseline scenario, where current treatment guidelines in South Africa are modelled, with two  
190 alternative scenarios, where measures to reduce dolutegravir resistance are modelled: i) upon  
191 entering failing dolutegravir compartments, people are switched to initiating PI-based ART within an  
192 average time of 6 or 12 months, and ii) upon an average time of 6 or 12 months on failing  
193 dolutegravir-based ART, people with intermediate or high level dolutegravir resistance are switched  
194 to PI-based ART within an average time of 6 months (representing the duration taken for druglevel-

195 and resistance testing, receiving results, and implementing treatment adjustments). These two  
196 modelled scenarios correspond closely to the RESOLVE interventions in which i) upon detection of  
197 viral failure on dolutegravir-based ART, all people are immediately switched to PI-based ART, and ii)  
198 upon detection of viral failure on dolutegravir-based ART, all people undergo drug-level- and  
199 resistance testing, followed by switch to PI-based ART in case of resistance, and continue on  
200 dolutegravir-based ART otherwise. The appendix (p15) provides further details on the scenarios.

201

## 202 **Sensitivity analyses**

203 We investigated the effects of mutation acquisition and reversion rates by varying viremia duration  
204 on dolutegravir-based ART rates from 2 to 6 months and the time for dolutegravir DRMs to revert to  
205 wild type from 6 months to 20 years. Further, we varied the hazard ratio for acquiring dolutegravir  
206 DRMs, comparing NRTI susceptible with resistant, from 1 (no impact) to 10. Similarly, we varied the  
207 hazard ratio for failing dolutegravir-based ART associated with high-level resistance from 2 to 4. We  
208 varied the probability of transmitting resistant strains from 100% (as likely as susceptible strain  
209 transmission) to 5% (20 times less likely than susceptible strain transmission). Finally, we varied the  
210 proportion of PWH with detectable drugs failing on dolutegravir-based ART from 0.3 to 1.

211 In addition to varying parameters one by one, we performed a multidimensional sensitivity analysis  
212 by implementing a Monte Carlo estimation of the first-order and total Sobol indices,<sup>25</sup> which are  
213 quantitative measures to assess the importance of parameters (and their interactions in the case of  
214 total Sobol indices) on the variability of modelled outcomes. The indices help determine relative  
215 parameter importance and identify knowledge gaps (appendix p14, p16).

## 216 **Role of the funding source**

217 The funders of the study did not participate in the study design, data collection, data analysis, data  
218 interpretation, and writing of the report. The corresponding author had full access to the data of this  
219 study and had the final responsibility for the decision to submit for publication.

220

## 221 Results

222 The model predicts a steep increase in the number of individuals on dolutegravir-based ART after its  
223 introduction in 2020, followed by a more modest but steady increase with numbers approaching  
224 eight million PWH on dolutegravir by 2040. The proportion with viral suppression in PWH on  
225 dolutegravir-based ART is estimated at around 93%, with those virally non-suppressed (viral load >  
226 1'000 copies per ml) comprised of an increasing proportion with dolutegravir resistance (Figure 2).  
227 Among those on dolutegravir-based ART, CD4 levels continue to improve (appendix, p 14)

### 228 Acquired and transmitted dolutegravir resistance

229 The model predicts that acquired dolutegravir resistance in people with virologic failure on  
230 dolutegravir-based ART will increase rapidly, from 18.5% (uncertainty range 12.5% to 25.4%) in 2023  
231 to 46.2% (uncertainty range 32.9% to 58.9%) in 2040 (Figure 2). There were substantial differences  
232 in the predicted levels of acquired dolutegravir resistance depending on the duration of failing  
233 dolutegravir-based ART, with a lower prevalence in people experiencing virologic failure for 6  
234 months or less and a higher prevalence among those experiencing failure for over 1.5 years. For  
235 transmitted drug resistance, the model predicts a slow but steady increase from 0.1% (uncertainty  
236 range 0.1% to 0.2%) in 2023 to 8.8% (uncertainty range 4.4% to 17.3%) in 2040. The rise of  
237 transmitted NNRTI resistance will be broken by introducing dolutegravir, but transmitted NNRTI  
238 resistance will remain prevalent at 7.7% in 2040 (Figure 2)

### 239 Counterfactual scenarios

240 We find that reducing the duration PWH remain viraemic whilst on dolutegravir-based ART would  
241 substantially reduce acquired dolutegravir resistance at the population level. Immediately switching  
242 to PI-based ART upon detecting of viral failure may reduce acquired dolutegravir resistance levels by  
243 2040 from 46.2% to 14.6% and 8.2%, depending on time to detection of viral failure. If using the  
244 mitigation strategy with GRT informed ART adjustment upon detection of viral failure, projected  
245 acquired dolutegravir resistance may be reduced to 11.3% and 6.3% (Figure 3). Transmitted  
246 dolutegravir resistance may be more than halved by 2040, from 8.8% to 2.1% and 1.1% in case of  
247 immediate switching to PI-based ART, or to 3.0% and 2.3% in case of GRT informed ART adjustment  
248 (Figure 3). Further details are available from the appendix (p15).

### 249 Sensitivity analyses

250 We assessed the impact of key model parameters one by one and also performed a multivariate  
251 sensitivity analysis. Perturbing one parameter at a time showed that dolutegravir resistance  
252 outcomes are affected by several variables, but the results from the main analysis were robust.



253 However, substantial deviations were observed for extreme parameter values, for example,  
254 assuming that the probability of transmission of dolutegravir resistance mutations was twenty times  
255 less likely than for NNRTIs, assuming much higher acquisition rates of dolutegravir resistance  
256 mutations or higher or lower reversion rates or proportion of people with detectable drug levels  
257 than in the main analysis. (appendix p16-18)

258 The variance-based global sensitivity analysis showed that predicted dolutegravir ADR was strongly  
259 influenced by assumptions regarding the proportion of people with detectable drug levels (Total  
260 Sobol' sensitivity index 0.34; 95% CI 0.30 to 0.38), and mutation acquisition rates (0.30; 95% CI 0.27  
261 to 0.33). Assumptions for the impact of NRTI resistance on dolutegravir resistance acquisition and of  
262 dolutegravir resistance on efficacy also affected ADR predictions (0.19; 95% CI 0.17 to 0.21 and 0.16;  
263 95% CI 0.14 to 0.18, respectively). The assumed dolutegravir DRM transmission probability  
264 compared to NNRTIs was the most important factor for the uncertainty in predicted dolutegravir  
265 TDR (0.64; 95% CI 0.56 to 0.70). Mutation reversion rates also affected TDR predictions (0.20; 95% CI  
266 0.16 to 0.23).

267

## 268 Discussion

### 269 Summary of findings

270 The transition to dolutegravir-based antiretroviral therapy (ART) has contained NNRTI resistance as a  
271 threat to the long-term effectiveness of ART. Still, reliance on INSTIs for first-line and second-line  
272 ART and prevention of HIV transmission carries the risk of emerging drug resistance to dolutegravir.  
273 We updated MARISA, a mathematical model of antiretroviral drug resistance, to study the  
274 emergence of resistance to dolutegravir in South Africa.<sup>16,17</sup> The model fitted the South African data  
275 well, with the modelled proportion of PWH with viral suppression (around 93%) in line with  
276 empirical data<sup>26</sup> and the 92% estimate reported by UNAIDS.<sup>27</sup> We found that the prevalence of  
277 acquired and transmitted dolutegravir resistance will likely increase. The 10% threshold of  
278 transmitted drug resistance, above which WHO recommends the replacement of a drug, could be  
279 reached by 2035, depending on the monitoring and switching strategies in place. During the same  
280 period, the prevalence of transmitted NNRTI will decline and then plateau at around 8%. Timely  
281 switching of PWH experiencing virologic failure to PI-based ART would substantially reduce acquired  
282 and transmitted drug resistance.

### 283 Modelled resistance in context with empirical data

284 Currently, viral suppression rates on dolutegravir are high. Although acquired drug resistance is rare,  
285 it can occur, especially in individuals with a compromised NRTI backbone.<sup>6,7</sup> Transmission of  
286 dolutegravir resistance has also recently been documented.<sup>23</sup> Programmatic data on dolutegravir  
287 resistance in resource-limited settings are scarce. Nationally representative HIV drug resistance  
288 surveys based on remnant routine diagnostic viral load samples in South Africa suggest increasing  
289 levels of dolutegravir resistance. Steegen *et al.*<sup>9</sup> found that in samples with viral load >1000  
290 copies/mL and detectable dolutegravir, resistance to dolutegravir increased from 2.7% in 2021 to  
291 11.1% in 2022, consistent with our predictions. Similar proportions of PWH with resistance  
292 mutations on failing dolutegravir-based ART have been recently reported by Tschumi *et al.* in  
293 Lesotho,<sup>7</sup> and by the WHO from other countries in Southern Africa.<sup>10</sup>

### 294 Duration on failing regimen

295 Our model predicts that acquired resistance may increase relatively quickly in the coming years.  
296 However, the predicted increase in resistance strongly depends on how long people with HIV remain  
297 viraemic on a failing dolutegravir-based regimen. There are often delays in switching, and some  
298 PWH may not be switched at all. A study linking medical and laboratory data from PWH on first-line  
299 ART in 52 South African clinics from 2007 to 2018 reported that only about 40% of PWH with  
300 confirmed virological failure were switched.<sup>28</sup> Among those who switched, the median time to

301 switch was about 16 months, with an interquartile range of 8 to 29 months.<sup>28</sup> Similarly, an analysis of  
302 a South African private sector ART program found that the median time from virologic failure to  
303 switching to second-line ART was about 13 months (interquartile range 8 to 22 months), with delays  
304 in switching associated with increased mortality.<sup>29</sup> Other studies from sub-Saharan Africa, including  
305 data from Central Africa, East Africa and West Africa, also found sub-optimal switching in adult HIV  
306 cohorts after virologic failure, with delays typically ranging from 4 to 17 months.<sup>30–33</sup>

307 Real-world evidence on effective switching strategies will come from the ongoing RESOLVE trial<sup>24</sup> in  
308 public-sector HIV clinics in Uganda and South Africa. The trial compares universal switching to PI-  
309 based second-line ART with switching guided by genotypic resistance tests, urine tenofovir  
310 adherence assays, and standard of care. In line with the association between the time spent on a  
311 failing regimen and resistance development, the model shows that such resistance mitigation  
312 strategies involving rapid switching to PI-based ART could effectively curb the increase in acquired  
313 and slow down the increase in transmitted dolutegravir resistance. Both strategies could keep the  
314 prevalence of dolutegravir resistance below 10% throughout the modelled period, i.e. up to 2040, in  
315 case of switching or drugleveldrug level- and resistance testing, respectively, within 6 months after  
316 virologic failure. Of note, the total number of people on PI-based ART differs strongly between the  
317 two mitigation strategies. Implementing the immediate PI-switch strategy would result in almost  
318 half of all people on ART in South Africa on PI-based ART by 2040.

### 319 **Strengths and limitations**

320 Strengths of our study include the combination of modelling the population-level epidemiology of  
321 the HIV epidemic in South Africa and of INSTI, NNRTI and NRTI drug resistance, taking into account  
322 the differences in the genetic barrier of these drug classes, and the model parametrisation using  
323 data from a large collaborative study of dolutegravir resistance.<sup>6</sup> Further, the model allowed us to  
324 assess the impact of public health interventions in counterfactual scenarios. Limitations include large  
325 parameter uncertainty, particularly regarding mutation pathways and acquisition- and reversion  
326 rates, which we addressed in the sensitivity analyses. The global sensitivity analysis helped unravel  
327 the relative importance of these parameters, and identified key knowledge gaps in our  
328 understanding of dolutegravir resistance dynamics. The limited data available on drug resistance  
329 mutation and their accumulation is a further limitation that may only be addressed in the future  
330 when more data becomes available. There is also uncertainty about the interactions between DRM's  
331 impact on viral fitness, including the role of compensatory mutations and the transmission of DRMs.  
332 This uncertainty affects transmitted drug resistance more than acquired, as reflected in the broader  
333 range of modelled outcomes for transmitted drug resistance. The assumed treatment cascade is a

334 simplification. For example, more complicated treatment histories or the dis- and re-engagement in  
335 care<sup>34</sup> that may favour the emergence of resistance were not explicitly modelled.

### 336 **Conclusions**

337 In conclusion, this modelling study indicates that dolutegravir resistance may increase considerably  
338 in South Africa: without changes in the management of virologic failure on dolutegravir-based ART,  
339 the emergence of transmitted dolutegravir resistance appears to be a question of when, not if, and  
340 acquired dolutegravir resistance may increase rapidly in the near future. Drug resistance mitigation  
341 strategies for those with virologic failure on dolutegravir-based ART, such as GRT-informed ART  
342 adjustment, could strongly reduce acquired and transmitted dolutegravir resistance if virologic  
343 failure is detected rapidly. We conclude that dolutegravir resistance surveillance including enhanced  
344 viral load monitoring and genotypic resistance testing should be strengthened, especially in settings  
345 with programmatic use of dolutegravir-based ART where people remain longer on failing ART.  
346 Greater access to genotypic resistance testing<sup>35</sup> as well as low-cost rapid point-of-care tests of  
347 antiretroviral drug levels,<sup>36</sup> and making generic darunavir/ritonavir available for around 200 US  
348 dollars per patient per year<sup>37</sup> should increase rates of switching to second-line ART and reduce  
349 delays, and thereby curbing the emergence and spread of dolutegravir resistance.

350

351 **Figures & Table**

352

353 **Table 1: Key dolutegravir resistance parameters.** Modelled prospective scenarios include baseline parameter values, and  
 354 ranges using pre-defined in- and decreased resistance parameters to derive an uncertainty interval. Other parameters used  
 355 in the model can be found in the appendix p4-11. Abbreviations: DRM: drug resistance mutation.


356

Parameter	Description	Baseline	Uncertainty range	
			Pessimistic choice in parameter values	Optimistic choice in parameter values
$1 / r_{DRM}$	Mean time for dolutegravir DRMs to revert (years)	2	3	2
$\alpha_{NRTI \rightarrow DTG}$	Impact of NRTI resistance on dolutegravir DRM acquisition rates (hazard ratio vs susceptible)	4	5	3
$\alpha_{impact\ DTG}$	Impact of high-level dolutegravir resistance on dolutegravir efficacy (hazard ratio vs susceptible)	3.24	2	4
$\Phi_{transmission\ DTG}$	Probability of dolutegravir resistance transmission compared to NNRTI resistance transmission	Same	Same	-20%
$\rho_{drug\ detect}$	Proportion with detectable drugs on failing dolutegravir-based ART	0.626	0.814	0.482

Note: For all scenarios, mutation rates were calculated based on assumed time of 3 months on failing dolutegravir-based ART (see appendix p7-8).

357


358



359  
360  
361  
362  
363  
364

**Figure 1: Simplified schematic overview of the adapted MARISA model.** The treatment dimension, including dolutegravir resistance acquisition on failing dolutegravir-based ART, is shown. Not displayed here are the dimensions for gender and CD4 levels, NNRTI- and NRTI resistance acquisition, and mortality. Details on the model structure can be found in the appendix p3-11.


365



366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377

**Figure 2: Modelled viral suppression on DTG-based ART, acquired and transmitted dolutegravir resistance.** Solid lines show baseline parameterisation regarding mutation reversion rates, impact of NRTI resistance on dolutegravir DRM acquisition, impact of dolutegravir resistance on its efficacy, transmission probability of dolutegravir DRMs in an HIV transmission event, and proportion with detectable drug levels on failing dolutegravir-based ART. Shaded areas correspond uncertainty intervals (see appendix p12). Dolutegravir rollout was started in 2020. Viral suppression (viral load below 1'000 copies per ml) on dolutegravir-based ART is high; depending on the model assumptions for dolutegravir resistance (see uncertainty range), between 6% and 8% of people on dolutegravir-based ART may be virally unsuppressed. Acquired dolutegravir resistance is defined as proportion of people on a failing dolutegravir-based ART with intermediate- or high-level dolutegravir resistance. Transmitted dolutegravir resistance is defined as proportion of newly diagnosed people with intermediate- or high-level dolutegravir resistance.

378



379

380

**Figure 3: Counterfactual scenario, modelling resistance emergence mitigation strategies.** Both strategies reduce the duration with viremia on dolutegravir-based ART. GRT-informed ART adjustment includes druglevel testing and genotypic resistance testing upon detecting virologic failure, followed by switching to PI-based ART in case of intermediate or high level dolutegravir resistance. Immediate PI switch includes switching people with virologic failure on dolutegravir-based ART immediately to PI-based ART. Modelled scenarios include projections assuming 6 and 12 months until virologic failure is detected (6 months: dark blue and dark red lines; 12 months: light blue and light red lines) upon which the respective strategy is implemented immediately. In case of druglevel and genotypic resistance testing, we assume an additional average duration of 6 months from detection of virologic failure to informed treatment adjustment. Acquired dolutegravir resistance is defined as proportion of people on a failing dolutegravir-based ART with intermediate- or high-level dolutegravir resistance. Transmitted dolutegravir resistance is defined as proportion of newly diagnosed people with intermediate- or high-level dolutegravir resistance..

391



## 392 **Authors' contributions**

393 RDK, RL, ME, and HFG conceptualised the study. TL, JJ, and RDK curated the data. TL, AH, JJ, and RDK  
394 devised the methodology. TL, NH, and JJ conducted the formal analysis and validation. TL, NH, and JJ  
395 managed the data. RDK provided project administration. AH and ME contributed resources. TL, NH,  
396 and JJ applied and adapted the software. HFG, RL, ME, LFJ, AH, and RDK provided supervision. TL  
397 created the figures. TL and RDK wrote the original draft of the manuscript. All authors reviewed the  
398 manuscript. TL, NH and RDK have directly accessed and verified the underlying data reported in the  
399 manuscript. All authors had the final responsibility for the decision to submit for publication.

400

## 401 **Declaration of interests**

402 RDK reports grants from the Swiss National Science Foundation, the National Institutes of Health,  
403 and Gilead Sciences. MJG has served as an ad hoc advisor to Gilead, ViiV and Merck. RDK reports  
404 grants from the Swiss National Science Foundation, the National Institutes of Health, and Gilead  
405 Sciences. H. F. G. has received grants from the Swiss National Science Foundation, Swiss HIV Cohort  
406 Study, Yvonne Jacob Foundation, University of Zurich's Clinical Research Priority Program, Zurich  
407 Primary HIV Infection, Systems.X, Bill and Melinda Gates Foundation, NIH, Gilead Sciences, ViiV and  
408 Roche; personal fees from Merck, Gilead Sciences, ViiV, Janssen, GSK, Johnson & Johnson, and  
409 Novartis for consultancy or data and safety monitoring board membership; and a travel grant from  
410 Gilead. LW has received grants from the ANRS emerging infectious diseases ANRS MIE, European  
411 Union (projects funded via H2020, Horizon Europe). SMI reports grant funding by the NIH National  
412 Institute on Alcohol Abuse and Alcoholism (U01-AA026209, payment to institution). F.C.S has  
413 received grants from the Italian Istituto Superiore di Sanità, Italian Ministry of Health, Italian  
414 Ministry of University and Scientific Research, University of Rome Tor Vergata, European Union  
415 (projects funded via H2020, Horizon Europe), ViiV Healthcare, Gilead Sciences, Inc, and Merck Sharp  
416 & Dohme, Inc.; personal fees for consultancy from ViiV Healthcare, Gilead Sciences, Inc, and Merck  
417 Sharp & Dohme, Inc. All other authors declare no competing interests.

418

## 419 **Acknowledgements**

420 This work was supported by the University Research Priority Program 'Evolution in Action', the Swiss  
421 National Science Foundation (324730\_207957), and the NIH National Institute of Allergy and  
422 Infectious Diseases under award number R01AI152772. We thank the DTG RESIST study group for  
423 helpful discussions.

## 424 **References**

- 425 1. WHO. Update of recommendations on first- and second-line antiretroviral regimens. Geneva,  
426 Switzerland:World Health Organization; WHO. 2019. p. 3.
- 427 2. WHO. WHO HIV Policy Adoption and Implementation Status in Countries [Internet]. HIV  
428 Treatment and Care Fact Sheet. 2022. p. 1–6. Available from:  
429 [https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/who-hiv-](https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/who-hiv-policy-adoption-and-implementation-status-in-countries_nov.pdf?sfvrsn=bb35e6ae_8)  
430 [policy-adoption-and-implementation-status-in-countries\\_nov.pdf?sfvrsn=bb35e6ae\\_8](https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/who-hiv-policy-adoption-and-implementation-status-in-countries_nov.pdf?sfvrsn=bb35e6ae_8)  
431 [Accessed: 18.04.2023]
- 432 3. UNAIDS. Global HIV & AIDS statistics — 2020 fact sheet | UNAIDS [Internet]. [cited 2020  
433 Jul 10]. Available from: <https://www.unaids.org/en/resources/fact-sheet>
- 434 4. Llibre JM, Pulido F, García F, García Deltoro M, Blanco JL, Delgado R. Genetic barrier to  
435 resistance for dolutegravir. *AIDS Rev.* 2015;17(1):56–64.
- 436 5. Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et al. Efficacy and safety  
437 of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or  
438 tenofovir for second-line treatment of HIV infection (NADIA ): week 96 results from a  
439 prospective, multicentre, open-label, factorial, randomised, no. *Lancet HIV.* 2022;1–13.
- 440 6. Loosli T, Hossmann S, Ingle SM, Okhai H, Kusejko K, Mouton J, et al. HIV-1 drug resistance in  
441 people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. *Lancet*  
442 *HIV.* 2023 Oct 10;
- 443 7. Tschumi N, Lukau B, Tlali K, Motaboli L, Kao M, Kopo M, et al. Emergence of acquired  
444 dolutegravir resistance in treatment-experienced people with HIV in Lesotho. *Clin Infect Dis.*  
445 2024 Apr;
- 446 8. Kamori D, Barabona G, Rugemalila J, Maokola W, Masoud SS, Mizinduko M, et al. Emerging  
447 integrase strand transfer inhibitor drug resistance mutations among children and adults on  
448 ART in Tanzania: findings from a national representative HIV drug resistance survey. *J*  
449 *Antimicrob Chemother.* 2023;78(3):779–87.
- 450 9. Steegen K. Close monitoring of dolutegravir resistance in patients with laboratory confirmed  
451 dolutegravir exposure: observations from a national HIV drug resistance survey in South  
452 Africa. Cape Town: XXX INTERNATIONAL WORKSHOP ON HIV DRUG RESISTANCE AND  
453 TREATMENT STRATEGIES; 2023.
- 454 10. WHO. HIV drug resistance: brief report 2024. Geneva: World Health Organization; 2024.
- 455 11. South African National Department of Health. 2023 ART Clinical Guidelines for the  
456 Management of HIV in Adults, Pregnancy and Breastfeeding, Adolescents, Children, Infants  
457 and Neonates. 2023;
- 458 12. Chimukangara B, Lessells RJ, Sartorius B, Gounder L, Manyana S, Pillay M, et al. HIV-1 drug  
459 resistance in adults and adolescents on protease inhibitor-based antiretroviral therapy in  
460 KwaZulu-Natal Province, South Africa. *J Glob Antimicrob Resist.* 2022;29:468–75.
- 461 13. Fox MP, Cutsem G V, Giddy J, Maskew M, Keiser O, Prozesky H, et al. Rates and predictors of  
462 failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. *J*  
463 *Acquir Immune Defic Syndr.* 2012;60(4):428–37.
- 464 14. Manasa J, Lessells RJ, Skingsley A, Naidu KK, Newell M-L, McGrath N, et al. High-Levels of  
465 Acquired Drug Resistance in Adult Patients Failing First-Line Antiretroviral Therapy in a Rural  
466 HIV Treatment Programme in KwaZulu-Natal, South Africa. *PLoS One.* 2013;8(8).

- 467 15. Venter WDF, Kaiser B, Pillay Y, Conradie F, Gomez GB, Clayden P, et al. Cutting the cost of  
468 South African antiretroviral therapy using newer, safer drugs. Vol. 107, SAMJ: South African  
469 Medical Journal. scieloza; 2017. p. 28–30.
- 470 16. Hauser A, Kusejko K, Johnson LF, Wandeler G, Riou J, Goldstein F, et al. Bridging the gap  
471 between hiv epidemiology and antiretroviral resistance evolution: Modelling the spread of  
472 resistance in south africa. PLoS Comput Biol. 2019;15(6):1–17.
- 473 17. Hauser A, Kusejko K, Johnson LF, Günthard HF, Riou J, Wandeler G, et al. Impact of scaling up  
474 dolutegravir on antiretroviral resistance in South Africa: A modeling study. PLoS Med.  
475 2020;17(12).
- 476 18. Chammartin F, Dao Ostinelli CH, Anastos K, Jaquet A, Brazier E, Brown S, et al. International  
477 epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012-2019. BMJ  
478 Open. 2020;10(5).
- 479 19. Johnson LF, Dorrington R. Thembisa version 4.1: A model for evaluating the impact of  
480 HIV/AIDS in South Africa [Internet]. 2018. Available from:  
481 <https://www.thembisa.org/publications>
- 482 20. Tao K, Rhee S-Y, Chu C, Avalos A, Ahluwalia AK, Gupta RK, et al. Treatment Emergent  
483 Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid  
484 Scoping Review. Viruses. 2023;15(9).
- 485 21. Rhee S-Y, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency  
486 virus reverse transcriptase and protease sequence database. Nucleic Acids Res.  
487 2003;31(1):298–303.
- 488 22. Canducci F, Barda B, Ceresola E, Spagnuolo V, Sampaolo M, Boeri E, et al. Evolution patterns  
489 of raltegravir-resistant mutations after integrase inhibitor interruption. Clin Microbiol Infect.  
490 2011;17(6):928–34.
- 491 23. Francois K, Van Onacker JD, Jordan MR, Journal I, Buteaue J, Pierre E, et al. First case report  
492 of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with  
493 tenofovir/lamivudine/dolutegravir use in mothers. AIDS. 2023;37(13):2097–9.
- 494 24. McCluskey S. A Randomized Clinical Trial to Evaluate Solutions for the Management of  
495 Virologic Failure on TLD in Sub-Saharan Africa (RESOLVE) [Internet]. ClinicalTrials.gov.  
496 Bethesda (MD): National Library of Medicine (US); [cited 2024 Jul 15]. Available from:  
497 <https://classic.clinicaltrials.gov/ct2/show/NCT05373758>
- 498 25. Saltelli A, Annoni P, Azzini I, Campolongo F, Ratto M, Tarantola S. Variance based sensitivity  
499 analysis of model output. Design and estimator for the total sensitivity index. Comput Phys  
500 Commun. 2010;181(2):259–70.
- 501 26. Dorward J, Sookrajh Y, Khubone T, van der Molen J, Govender R, Phakathi S, et al.  
502 Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for  
503 people with HIV in South Africa: a retrospective cohort study. Lancet HIV. 2023;10(5):e284–  
504 94.
- 505 27. UNAIDS: Joint United Nations Programme On HIV/AIDS. UNAIDS data 2023. Geneva; 2023.
- 506 28. Hermans LE, Carmona S, Nijhuis M, Tempelman HA, Richman DD, Moorhouse M, et al.  
507 Virological suppression and clinical management in response to viremia in South African HIV  
508 treatment program: A multicenter cohort study. PLoS Med. 2020;17(2):e1003037.
- 509 29. Bell Gorrod H, Court R, Schomaker M, Maartens G, Murphy RA. Increased Mortality with

- 510 Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa. *J Acquir*  
511 *Immune Defic Syndr.* 2020;84(1):107–13.
- 512 30. Petersen ML, Tran L, Geng EH, Reynolds SJ, Kambugu A, Wood R, et al. Delayed switch of  
513 antiretroviral therapy after virologic failure associated with elevated mortality among HIV-  
514 infected adults in Africa. *AIDS.* 2014;28(14):2097–107.
- 515 31. Ssempijja V, Nakigozi G, Chang L, Gray R, Wawer M, Ndyanabo A, et al. Rates of switching to  
516 second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic,  
517 and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda.  
518 *BMC Infect Dis.* 2017;17(1).
- 519 32. Haas AD, Keiser O, Balestre E, Brown S, Bissagnene E, Chimbetete C, et al. Monitoring and  
520 switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa:  
521 Collaborative analysis. *Lancet HIV.* 2015;2(7):e271–8.
- 522 33. Laurent C, Kouanfack C, Laborde-Balen G, Aghokeng AF, Mbougua JBT, Boyer S, et al.  
523 Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical  
524 monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall  
525 ANRS 12110/ESTHER): A randomised non-inferiority trial. *Lancet Infect Dis.* 2011;11(11):825–  
526 33.
- 527 34. Euvrard J, Timmerman V, Keene CM, Phelanyane F, Heekes A, Rice BD, et al. The cyclical  
528 cascade of HIV care: Temporal care engagement trends within a population-wide cohort.  
529 *PLoS Med.* 2024;21(5).
- 530 35. de Oliveira T, Baxter C. Investing in Africa’s scientific future. *Science.* 2024 Mar  
531 6;383(6678):eadn4168.
- 532 36. Dorward J, Lessells R, Govender K, Moodley P, Samsunder N, Sookrajh Y, et al. Diagnostic  
533 accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug  
534 resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy. *J*  
535 *Int AIDS Soc.* 2023;26(9).
- 536 37. World Health Organization. Innovative agreement launches affordable, optimal second-line  
537 HIV treatment in low- and middle-income countries [Internet]. 2021. Available from:  
538 [https://unitaid.org/news-blog/innovative-agreement-affordable-optimal-second-line-hiv-](https://unitaid.org/news-blog/innovative-agreement-affordable-optimal-second-line-hiv-treatment/#en)  
539 [treatment/#en](https://unitaid.org/news-blog/innovative-agreement-affordable-optimal-second-line-hiv-treatment/#en)
- 540